Download PDF
Dtsch Med Wochenschr 2021; 146(17): 1152-1158
DOI: 10.1055/a-0949-4889
Übersicht

Schwere Organmanifestationen bei rheumatischen Erkrankungen

Severe organ manifestations in rheumatic diseases
Florian Günther
,
Martin Fleck
› Further Information
Also available at
    Permissions and Reprints

Bei Patienten mit entzündlich-rheumatischen Erkrankungen können sich schwere Organmanifestationen entwickeln, die eine Behandlung auf einer Intensivstation (ICU) erforderlich machen. Das frühzeitige Erkennen eines drohenden Organversagens ist von größter Bedeutung für das Outcome und die langfristige Prognose. In diesem Beitrag werden intensivmedizinisch relevante Organmanifestationen hinsichtlich der Diagnostik und Therapie vorgestellt.

Abstract

Several inflammatory rheumatic diseases can severely affect any organ system and require immediate intervention and intensive care admission. The early detection of impending organ failure and the underlying rheumatic disease is of paramount importance for the prognosis and outcome of affected patients. Therefore, a thorough knowledge of the potential life threatening organ manifestations of systemic rheumatic diseases is of particular interest for clinicians working in intensive care. This paper provides an overview of diagnostic steps and therapy of organ manifestations in critically ill patients with underlying systemic rheumatic diseases. The presentation of the relevant systemic rheumatic diseases is structured according to the most important organ systems, i. e. the respiratory system, the kidney and the cardiovascular system. Furthermore, there is a focus in this paper on macrophage activation syndrome (MAS) as a potentially lethal complication of several rheumatic diseases and the catastrophic antiphospholipid syndrome (CAPS) as a rare cause of multi organ failure.

Schlüsselwörter

Intensivmedizin - entzündlich-rheumatische Systemerkrankungen - Organmanifestationen

Key words

intensive care - inflammatory rheumatic diseases - organ manifestations


Publication History

Article published online:
26 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Brünnler T, Susewind M, Hoffmann U. et al. Outcomes and Prognostic Factors in Patients with Rheumatologic Diseases Admitted to the ICU. Intern Med 2015; 54: 1981-1987
    CrossrefPubMedGoogle Scholar
  • 2 Larcher R, Pineton de Chambrun M, Garnier F. et al. One-year outcome of critically ill patients with systemic rheumatic disease: a multi-center cohort study. Chest 2020; 158 (03) 1017-1026
    CrossrefPubMedGoogle Scholar
  • 3 Hellmich B, Henes J, Hetzel JP. Pulmonale Manifestationen von Vaskulitiden. In: Kreuter M, Costabel U, Herth F. et al. Seltene Lungenerkrankungen. 1. Aufl.. Berlin, Heidelberg: Springer; 2016: 91-109
    CrossrefGoogle Scholar
  • 4 Schreiber J, Knolle J, Kachel R. et al. Differenzialdiagnostik der diffusen alveolären Hämorrhagie. Pneumologie 2006; 60: 347-354
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Schnabel A, Gross WL. Pulmonale Vaskulitis. Pneumologie 2000; 54: 232-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Jones RB, Tervaert JW, Hauser T. et al. Rituximab versus cyclophosphamid in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
    CrossrefPubMedGoogle Scholar
  • 7 Stone JH, Merkel PA, Spiera R. et al. Rituximab versus cyclophosphamid for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
    CrossrefPubMedGoogle Scholar
  • 8 Walsh M, Merkel PA, Peh CA. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 13: 622-631
    CrossrefPubMedGoogle Scholar
  • 9 Hellmich B, Löffler C. Was sind die Indikationen für Rescue-Verfahren. Z Rheumatol 2019; 78: 955-966
    CrossrefPubMedGoogle Scholar
  • 10 Delvino P, Monti S, Balduzzi S. et al. The role of extra-corporal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associacated vasculitis: report of two cases and review of the literature. Rheumatol Int 2019; 39: 367-375
    CrossrefPubMedGoogle Scholar
  • 11 Krause A. Lungenbeteiligung bei rheumatischen Erkrankungen. arthritis + rheuma 2018; 38: 15-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Au K, Reed G, Curtis JR. et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70 (05) 785-791
    CrossrefPubMedGoogle Scholar
  • 13 Sato S, Hoshino K, Satoh T. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193-2200
    CrossrefPubMedGoogle Scholar
  • 14 Hamman L, Rich A. Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51: 154-163
    PubMedGoogle Scholar
  • 15 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381: 1718-1727
    CrossrefPubMedGoogle Scholar
  • 16 Distler O, Highland KB, Gahlemann M. et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380 (26) 2518-2528
    CrossrefPubMedGoogle Scholar
  • 17 Doyle TJ, Dhillon N, Madan R. et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrom: A multicenter retrospective case review. J Rheumatol 2018; 45: 841-850
    CrossrefPubMedGoogle Scholar
  • 18 Ruscitti P, Cipriani P, Ciccia F. et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmune Rev 2017; 16: 16-21
    CrossrefPubMedGoogle Scholar
  • 19 Arlet JB, Le Thi Huong D, Marinho A. et al. Reactive haemophagocytic syndrome in adult-onset Still`s disease: a report of six patients and a review of the literature. Ann Rheum Dis 2006; 65: 1596-1601
    CrossrefPubMedGoogle Scholar
  • 20 Grom AA, Horne AC, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016; 12: 259-268
    CrossrefPubMedGoogle Scholar
  • 21 Garcia D, Erkan D. Diagnosis and Managment of the Antiphospholipid Syndrome. NEJM 2018; 378: 2010-2021
    CrossrefPubMedGoogle Scholar
  • 22 Legault K, Schunemann H, Hillis C. et al. McMaster RARE-Bestpractice clinical practice guideline on diagnosis and managment of the catastrophic antiphospholipid syndrome. J Thromb Haemost 2018; 16: 1656-1664
    CrossrefPubMedGoogle Scholar
  • 23 Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev 2017; 13: 206-218
    CrossrefPubMedGoogle Scholar
  • 24 Cervera R, Piette JC, Font J. et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027
    CrossrefPubMedGoogle Scholar
  • 25 Nazir S, Tachamo N, Lohani S. et al. Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review. Coronary Artery Disease 2017; 28: 332-335
    CrossrefPubMedGoogle Scholar
  • 26 Rav-Acha M, Plot L, Peled N. et al. Coronary involvement in Takayasu’s arteritis. Autoimmun Rev 2007; 6: 566-571
    CrossrefPubMedGoogle Scholar
  • 27 Schrader ML, Hochman JS, Bulkley BH. The heart in polyarteriitis nodosa. A clinicopathologic study. Am Heart J 1985; 109 (06) 1353-1359
    CrossrefPubMedGoogle Scholar